SeaStar Medical Holding Corp raised approximately $3.3 million in gross proceeds from the immediate cash exercise of 854,002 outstanding warrants at a negotiated reduced price of $3.866 per share. In exchange for this accelerated exercise, the company issued new unregistered Series A and Series B warrants exercisable for an aggregate of 1,708,004 shares at an exercise price of $3.616 per share. The transaction closed on October 5, 2026, with H.C. Wainwright & Co. acting as the exclusive placement agent. SeaStar Medical intends to use the net proceeds for general corporate purposes, including working capital and capital expenditures. The company is a commercial-stage healthcare firm developing treatments for critically ill patients facing organ failure.
